In 22.2% of trials, there was a survival benefit with the next-in-class agent. Less than one-quarter of next-in-class cancer drugs demonstrated a survival benefit over existing in-class agents in head ...
Add Yahoo as a preferred source to see more of our stories on Google. For the first time, the Lee County Education Foundation will soon announce a Head of Class winner for a middle school. Back in ...
Researchers looked specifically at head-to-head randomized clinical trials of next-in-class cancer drugs against existing agents in the same class. Less than one-quarter of next-in-class cancer drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results